These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 20490905)

  • 21. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.
    Atlas SA
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl B):9-20. PubMed ID: 17970613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Classical nephroprotection: Renin angiotensin aldosterone system inhibitors].
    Egocheaga MI; Drak Y; Otero V
    Semergen; 2023 Jun; 49 Suppl 1():102018. PubMed ID: 37355297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z; Winaver J; Feuerstein GZ
    Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.
    Kunz R; Friedrich C; Wolbers M; Mann JF
    Ann Intern Med; 2008 Jan; 148(1):30-48. PubMed ID: 17984482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The future of renin inhibition].
    Uresin AY; Baran E
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():32-8. PubMed ID: 20019475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
    Ruggenenti P; Cravedi P; Remuzzi G
    Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct Renin inhibition: promising treatment in renoprotection?
    Loriga G
    Recent Pat Cardiovasc Drug Discov; 2010 Jun; 5(2):113-9. PubMed ID: 20438446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
    Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
    Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized?
    Pappoe LS; Winkelmayer WC
    Drugs Aging; 2010 Feb; 27(2):87-94. PubMed ID: 20104936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system.
    Berl T
    J Renin Angiotensin Aldosterone Syst; 2009 Mar; 10(1):1-8. PubMed ID: 19286752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
    Cohen DL; Townsend RR
    J Am Soc Nephrol; 2009 Aug; 20(8):1666-8. PubMed ID: 18776118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.
    Tylicki L; Jakubowska A; Lizakowski S; Świetlik D; Rutkowski B
    J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):145-52. PubMed ID: 25324423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
    Remuzzi G; Perico N; Macia M; Ruggenenti P
    Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.
    Parving HH; Andersen S; Jacobsen P; Christensen PK; Rossing K; Hovind P; Rossing P; Tarnow L
    Semin Nephrol; 2004 Mar; 24(2):147-57. PubMed ID: 15017527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.